Clinical trials: Tissue Grafts
Degenerative Joint Disease, Congenital Deformity
Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
STUDY OBJECTIVES: To demonstrate equivalent clinical and radiologic outcomes as "gold standard" (Autologous Bone Graft) in a representative clinical model (hindfoot fusions) STUDY HYPOTHESIS: Augment® Injectable is an equivalent…
- Conditions
- Degenerative Joint Disease, Congenital Deformity, Arthritis, Osteoarthritis
- Trial name
- NCT01305356
- Testing
- Augment® Injectable Bone Graft, Autologous bone graft
- Where
- 25 sites in United States, Canada
- Volunteers
- 299 people
- Sponsor
- BioMimetic Therapeutics
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Chronic Spontaneous Urticaria
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.
- Trial name
- NCT02477332
- Testing
- QGE031, Omalizumab
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 382 people
- Sponsor
- Novartis Pharmaceuticals
Bone Cysts, Bone Atrophy
Gene-activated Bone Substitute for Maxillofacial Bone Regeneration
The purpose of this study is to evaluate the safety and efficacy of the gene-activated bone substitute consisting of octacalcium phosphate and plasmid DNA encoding vascular endothelial growth factor (VEGF) for maxillofacial bone…
- Conditions
- Bone Cysts, Bone Atrophy, Bone Deformity, Bone Fracture
- Trial name
- NCT03076138
- Testing
- Gene-activated matrix (OCP + plasmid DNA with VEGF gene)
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Histograft Co., Ltd.
Diabetic Foot Ulcer
Trial of Dehydrated Human Amnion/Chorion Membrane (dHACM) In the Management of Diabetic Foot Ulcers
The objective of this study is to evaluate the percentage of patients with complete diabetic foot ulcer (DFU) closure following up to 12 weeks of treatment with either dehydrated human amnion/chorion membrane (dHACM) plus…
- Trial name
- NCT01693133
- Testing
- Standard of Care: Moist Wound Therapy and Offloading, EpiFix plus Standard of Care
- Where
- 20 sites in United States
- Volunteers
- 132 people
- Sponsor
- MiMedx Group, Inc.
Pelvic Organ Prolapse
Soft Tissue Graft for Repair of Pelvic Organ Prolapse
The purpose of this Study is to collect information about the performance of the Surgisis® Soft Tissue Graft ("Study Product") for the repair of pelvic organ prolapse in women.
- Trial name
- POP (NCT01827774)
- Testing
- Surgisis® Soft Tissue Graft
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Cook Group Incorporated
Coronary Artery Disease
Photochemical Tissue Passivation Treatment of Saphenous Vein Grafts in CABG
Early feasibility study of the DurVena Photochemical Tissue Passivation (PTP) device for treatment of saphenous vein grafts in participants undergoing elective coronary artery bypass graft (CABG) surgery.
- Trial name
- NCT06150872
- Testing
- DurVena Photochemical Tissue Passivation
- Where
- Uzbekistan
- Volunteers
- 4 people
- Sponsor
- DurVena, Inc.
Diabetic Foot Ulcer
Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Diabetic Foot Ulcers
This is a prospective case series evaluating the efficacy and safety of NeoThelium FT Amnion Skin Graft in the Mangement of Diabetic Foot Ulcers
- Trial name
- NCT07039396
- Testing
- NeoThelium FT (HCT/P 361)
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- NuScience Medical Biologics, LLC
Psoriasis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to…
- Trial name
- NCT01815424
- Testing
- CP-690,550
- Where
- 24 sites in China, South Korea and 1 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Ulcer Healing, Diabetic Foot Ulcer
Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot Ulcers
The goal of this clinical pilot is to collect patient outcome data on a commercially available, keratin-based skin substitute matrix: ProgenaMatrix®.
- Trial name
- NCT05797285
- Testing
- human keratin graft
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- ProgenaCare Global, LLC
Anal Fistula
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
The LIFT+Biodesign® study is a post-market observational study to evaluate the rate of fistula closure in patients with persistent trans-sphincteric anal fistula who receive the Biodesign® Tissue graft as part of their LIFT…
- Trial name
- LIFT+Graft (NCT01602081)
- Testing
- reinforce soft tissue
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Cook Group Incorporated
Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at…
- Trial name
- NCT01186744
- Testing
- CP-690,550
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Skin Wound
Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children
This phase II trial aims to evaluate the efficacy and safety of EHSG-KF (synonym denovoSkin) in comparison to meshed STSG in adults and children with full-thickness Skin defects.
- Trial name
- NCT03394612
- Testing
- EHSG-KF, STSG
- Where
- 7 sites in Italy, Netherlands and 1 more
- Volunteers
- 21 people
- Sponsor
- CUTISS AG
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis
The primary purpose for this study is to help answer the following research questions The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
- Trial name
- NCT01107457
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Denmark
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Punch Biopsy Wounds, Healing Times
Healing of Punch Graft Wounds. Comparative Study Between MariGen and Oasis: a Non-inferiority Study
The objective is to determine, if healing of punch biopsy wounds treated with the fish skin derived MariGen Wound dressing is non-inferior to healing with wounds treated with pig intestines derived Oasis Sheet wound dressing.
- Trial name
- NCT01917591
- Testing
- Punch biopsies treated with MariGen Wound ECM dressing, Punch biopsies treated with Oasis ECM dressing
- Where
- Iceland
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Kerecis Ltd.
Systemic Juvenile Idiopathic Arthritis (SJIA)
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
- Trial name
- ß-SPECIFIC 4 (NCT02296424)
- Testing
- ACZ885 150 mg (Canakinumab)
- Where
- 50 sites in United States, Austria and 14 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Foot Ulcer
Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
The purpose of this study is to determine whether a weekly application of EpiFix human amniotic membrane is more effective than a biweekly application (every two weeks) in the treatment of diabetic foot ulcers.
- Trial name
- NCT01657474
- Testing
- Weekly application of EpiFix plus standard of care, Biweekly application of EpiFix plus standard of care
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- MiMedx Group, Inc.
Urticaria
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg Q.D., compared to Levocetirizine 5 mg Q.D. and placebo for the treatment of Chronic Idiopathic Urticaria.
- Trial name
- NCT00421109
- Testing
- Bilastine, Levocetirizine
- Where
- 50 sites in Argentina, Belgium and 5 more
- Volunteers
- 522 people
- Sponsor
- Faes Farma, S.A.
Wound
Evaluation of the Safety and Effectiveness of ALLEVYN Gentle Border
The clinical study will evaluate the safety and effectiveness of the ALLEVYN Gentle Border. The study is a post-market clinical follow-up to assess clinical performance and safety of ALLEVYN Gentle Border with new wound contact…
- Trial name
- NCT03877484
- Testing
- ALLEVYN Gentle border
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- Smith & Nephew Orthopaedics AG